TWI488627B - 左氧氟沙星或其鹽或該等之溶劑合物之用途 - Google Patents

左氧氟沙星或其鹽或該等之溶劑合物之用途 Download PDF

Info

Publication number
TWI488627B
TWI488627B TW099146206A TW99146206A TWI488627B TW I488627 B TWI488627 B TW I488627B TW 099146206 A TW099146206 A TW 099146206A TW 99146206 A TW99146206 A TW 99146206A TW I488627 B TWI488627 B TW I488627B
Authority
TW
Taiwan
Prior art keywords
levofloxacin
eye
eye drops
genus
conjunctivitis
Prior art date
Application number
TW099146206A
Other languages
English (en)
Chinese (zh)
Other versions
TW201129364A (en
Inventor
長野敬
阪中浩二
中村雅胤
河津剛一
伊吹肇
坂本佳代子
Original Assignee
參天製藥股份有限公司
第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 參天製藥股份有限公司, 第一三共股份有限公司 filed Critical 參天製藥股份有限公司
Publication of TW201129364A publication Critical patent/TW201129364A/zh
Application granted granted Critical
Publication of TWI488627B publication Critical patent/TWI488627B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW099146206A 2010-02-25 2010-12-28 左氧氟沙星或其鹽或該等之溶劑合物之用途 TWI488627B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25

Publications (2)

Publication Number Publication Date
TW201129364A TW201129364A (en) 2011-09-01
TWI488627B true TWI488627B (zh) 2015-06-21

Family

ID=44506417

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099146206A TWI488627B (zh) 2010-02-25 2010-12-28 左氧氟沙星或其鹽或該等之溶劑合物之用途

Country Status (16)

Country Link
US (1) US20120316158A1 (https=)
EP (1) EP2540299B1 (https=)
JP (3) JP5600056B2 (https=)
KR (2) KR20130043611A (https=)
CN (1) CN102770141A (https=)
BR (1) BR112012021247A2 (https=)
CA (1) CA2791190C (https=)
EA (1) EA201290827A1 (https=)
ES (1) ES2568647T3 (https=)
MX (1) MX349603B (https=)
MY (1) MY183483A (https=)
NZ (1) NZ602126A (https=)
PH (2) PH12016501747B1 (https=)
SG (1) SG183427A1 (https=)
TW (1) TWI488627B (https=)
WO (1) WO2011104981A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
WO2003028664A2 (en) * 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
EP1458391B1 (en) * 2001-11-30 2007-09-05 LG Life Sciences Ltd. A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
ES2671342T3 (es) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Antibióticos nebulizados para terapia de inhalación
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use

Also Published As

Publication number Publication date
SG183427A1 (en) 2012-09-27
NZ602126A (en) 2013-10-25
WO2011104981A1 (ja) 2011-09-01
JP5600056B2 (ja) 2014-10-01
MX2012009844A (es) 2012-09-21
PH12016501747A1 (en) 2019-02-11
JP2013241464A (ja) 2013-12-05
KR20130043611A (ko) 2013-04-30
JP5674882B2 (ja) 2015-02-25
EA201290827A1 (ru) 2013-03-29
EP2540299A4 (en) 2013-07-24
CN102770141A (zh) 2012-11-07
BR112012021247A2 (pt) 2018-04-03
AU2010346703A1 (en) 2012-09-20
ES2568647T3 (es) 2016-05-03
CA2791190C (en) 2017-12-12
KR20170070265A (ko) 2017-06-21
JP2011195564A (ja) 2011-10-06
PH12012501674A1 (en) 2012-11-05
PH12016501747B1 (en) 2022-06-22
US20120316158A1 (en) 2012-12-13
EP2540299A1 (en) 2013-01-02
EP2540299B1 (en) 2016-04-13
CA2791190A1 (en) 2011-09-01
MX349603B (es) 2017-08-03
MY183483A (en) 2021-02-20
TW201129364A (en) 2011-09-01
JP2012162532A (ja) 2012-08-30
HK1177887A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
TWI488627B (zh) 左氧氟沙星或其鹽或該等之溶劑合物之用途
MX2014011468A (es) Gotas para los ojos que contienen diquafosol.
CA2987783A1 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
US20130338126A1 (en) Ophthalmic Suspension for Ocular Use
Marchino et al. Acute-onset endophthalmitis caused by alloiococcus otitidis following a dexamethasone intravitreal implant
JPWO2016072440A1 (ja) 眼科用水性組成物
JP6487609B1 (ja) 点眼剤
JP6867288B2 (ja) リファマイシンの眼科用組成物およびその使用
Tabbara et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%
WO2016196989A1 (en) Topical composition
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
RU2493823C1 (ru) Глазные капли, обладающие противоинфекционным, противовоспалительным и противоаллергическим действием
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
CN114129590B (zh) 一种眼用组合物及其制备方法与应用
Tabbara et al. Effects of fusidic acid on staphylococcal keratitis.
Booysen South African Guide to topical ophthalmic drugs
RU2293563C1 (ru) Способ лечения инфекционных воспалительных заболеваний глаз
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
Adamiec-Mroczek et al. Efficient antiseptic prophylaxis in the era of antibiotic resistance
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
JP2004049228A (ja) 麦粒腫の病態モデル動物およびその作製方法
CN120919047A (zh) 一种左氧氟沙星温敏型凝胶滴眼剂及其制备方法
Khuu et al. Contact Lens-Related Corneal Ulcer: A Teaching Case Report.
Esporcatte et al. Panoftalmite com celulite orbitária após implante de drenagem em glaucoma congênito
Hori et al. Severe methicillin-resistant staphylococcus aureus infection after multilayer amniotic membrane transplantation

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees